Autopsy report · NCT04985968

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

“Due to futility”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 171 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

InDex Pharmaceuticals

Sponsor type

Industry

Conditions

Ulcerative Colitis

Interventions

Cobitolimod 250 mg; Cobitolimod 500 mg; Placebo

Participants

171

Sites

203

Countries

Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Croatia, Denmark, France, Georgia, Germany, Hungary and more

Trials that died the same way

• Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury
  “Futility” (78% match in meaning)
• Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection
  “for futility” (76% match in meaning)
• Prevention of Unexplained Recurrent Abortion by Enoxaparine
  “Stopped for futility” (67% match in meaning)
• The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
  “futility ground” (61% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.